

CITATION REPORT

List of articles citing

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

DOI: 10.1177/1758835919833519

Therapeutic Advances in Medical Oncology, 2019, 11, 1758835

Source: <https://exaly.com/paper-pdf/73481368/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
194	Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics. <i>Cancer Research</i> , 2019 , 79, 5693-5698	10.1	0
193	Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. 2019 , 178, 401-408		5
192	CAR T cells for brain tumors: Lessons learned and road ahead. 2019 , 290, 60-84		86
191	A clinical evaluation of treatments that target cell cycle machinery in breast cancer. 2019 , 20, 2305-2315		8
190	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). 2019 , 121, 985-990		3
189	What therapies are on the horizon for HER2 positive breast cancer?. 2019 , 19, 811-822		2
188	Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. 2019 , 10, 1939		26
187	Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. 2019 , 10, 5504-5517		39
186	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. 2019 , 4, 34		125
185	PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer. 2019 , 19, 233		26
184	The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis. 2019 , 9,		10
183	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. 2019 , 19, 399-404		15
182	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. <i>Cancers</i> , 2019 , 11,	6.6	75
181	Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. 2020 , 104, 575-587		129
180	Notch Signaling in Breast Cancer: A Role in Drug Resistance. 2020 , 9,		17
179	A risk-stratified approach to colorectal cancer prevention and diagnosis. 2020 , 17, 773-780		16
178	Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2409-2421	6.1	25

177	A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1866-1874	6.1	4
176	The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell Death. 2020 , 85, 1277-1287		1
175	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020 , 12,	6.6	7
174	Effect of polyphenols on HER2-positive breast cancer and related miRNAs: Epigenomic regulation. 2020 , 137, 109623		4
173	A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. 2020 , 99, e22886		0
172	Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. 2020 , 128, 573-582		1
171	Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. 2020 , 99, e22331		1
170	Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
169	Evolving standards of care and new challenges in the management of HER2-positive breast cancer. 2020 , 70, 355-374		24
168	AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies. 2020 ,		2
167	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 5820-5829	12.9	17
166	Cell Cycle and Factors Involved in Inhibition or Progression of Breast Cancer. 2020 ,		
165	Prognostic value of the androgen receptor in addition to the established hormone receptors and HER2 status for predicting survival in women with early breast cancer. 2020 ,		1
164	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020 , 12,	6.6	4
163	Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients. 2020 , 17, 187-190		1
162	CircRNA_103809 Suppresses the Proliferation and Metastasis of Breast Cancer Cells by Sponging MicroRNA-532-3p (miR-532-3p). 2020 , 11, 485		13
161	Understanding Breast cancer: from conventional therapies to repurposed drugs. 2020 , 151, 105401		9
160	Association between serum HER2/ErbB2 levels and coronary artery disease: a case-control study. 2020 , 18, 124		2

159	Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations. 2020 , 25, 843-868	22
158	6-Color/1-Target Immuno-SERS Microscopy on the Same Single Cancer Cell. 2020 , 12, 32321-32327	6
157	Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. 2020 , 117, 16500-16508	15
156	Production of the Extracellular Part of the ErbB2 Receptor for the Study of Immunobiologicals. 2020 , 46, 327-333	
155	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. 2020 , 5, 7-22	1
154	Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going. 2020 , 147, 261-278	20
153	Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae. <i>Cancers</i> , 2020 , 12,	6.6 15
152	Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models. 2020 , 9,	29
151	Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells. 2020 , 21,	13
150	Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. 2020 , 10,	2
149	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. 2020 , 12, e11498	18
148	Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. 2020 , 11, 1792	14
147	Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. 2021 , 113, 7-8	1
146	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. 2021 , 72, 123-135	35
145	Margetuximab for the treatment of HER2-positive metastatic breast cancer. 2021 , 21, 127-133	12
144	Synthesis of N-2(5H)-furanonyl sulfonyl hydrazone derivatives and their biological evaluation in vitro and in vivo activity against MCF-7 breast cancer cells. 2021 , 107, 104518	15
143	Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. 2021 , 36, 737-747	5
142	Experimental HER2- targeted therapies for biliary tract cancer. 2021 , 30, 389-399	5

141	Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). 2021 , 28, 216-225			5
140	Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer. 2021 , 36, 124-125			1
139	Ultrasensitive detection of cyclin D1 by a self-enhanced ECL immunosensor based on BiS quantum dots. 2021 , 146, 2057-2064			2
138	MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. 2021 , 24, 153-163			4
137	The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China. 2021 , 20, 15330338211037812			1
136	Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. 2021 , 147, 2447-2458			0
135	Arsenic hexoxide has differential effects on cell proliferation and genome-wide gene expression in human primary mammary epithelial and MCF7 cells. 2021 , 11, 3761			4
134	Vaccinia virus-based vector against infectious diseases and tumors. 2021 , 17, 1578-1585			4
133	The Exciting New Field of HER2-Low Breast Cancer Treatment. <i>Cancers</i> , 2021 , 13,	6.6	20	
132	Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review. 2021 , 27, 1468-1476			1
131	Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. 2021 , 23, 1761-1768			1
130	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. 2021 , 23, 42			3
129	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. 2021 , 12, 628690			35
128	Ultrasound-triggered herceptin liposomes for breast cancer therapy. 2021 , 11, 7545			18
127	Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: Another Paradigm Shift?. <i>Cancers</i> , 2021 , 13,	6.6	12	
126	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and prior HER2-directed regimens. 2021 , 188, 449-458			
125	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. 2021 , 21, 811-824			2
124	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.. 2021 , 2, 400-413			8

123	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. 2021 , 22,	7
122	Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. 2021 , 10, 1176-1183	4
121	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. 2021 , 6,	3
120	Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. 2021 , 12, 669474	16
119	Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings. 42,	
118	Dimer targeting peptide mediated precise and controllable drug delivery by upconversion nanocarriers for breast cancer therapy. 2021 , 203, 109597	5
117	Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management. 2021 , 261, 67-73	0
116	Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. 2021 , 12, 2699	8
115	A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid. 2021 , 32, 1094-1104	3
114	Characteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center. 2021 , 9, 1-9	
113	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. 2021 , 12, 696960	6
112	New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. 2021 , 81, 666-678	0
111	Targeting in -positive breast cancer: what are the opportunities and the challenges?. 2021 , 15, 609-613	0
110	Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2. 2021 , 12, 614673	1
109	[New therapeutic strategies in HER2-positive breast cancer]. <i>Bulletin Du Cancer</i> , 2021 ,	2.4
108	Accurate prediction of breast cancer survival through coherent voting networks with gene expression profiling. 2021 , 11, 14645	1
107	CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy. 2021 ,	1
106	An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer. 2021 , 21, 1025-1036	1

105	Breast Cancer Treatments: Updates and New Challenges. 2021 , 11,		16
104	Role of Phytonutrients in Nutrigenetics and Nutrigenomics Perspective in Curing Breast Cancer. 2021 , 11,		5
103	The aluminium-[F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. 2021 , 6, 30		7
102	Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer. 2021 , 45, 128134		4
101	Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. 2021 , 21, 967		3
100	Neue Therapiestrategien beim HER2-positiven fortgeschrittenen, inoperablen bzw. metastasierten Mammakarzinom. 2021 , 18, 240-253		
99	Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells. 2021 , 69, 558-567		4
98	New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. 2021 , 46, 116340		1
97	Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis.. 2022 , 15, 1-13		4
96	Prospects and challenges of anticancer agents delivery via chitosan-based drug carriers to combat breast cancer: a review. <i>Carbohydrate Polymers</i> , 2021 , 268, 118192	10.3	14
95	MicroRNAs as a clue to overcome breast cancer treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2021 , 1	9.6	5
94	Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. <i>Biochemical and Biophysical Research Communications</i> , 2021 , 576, 59-65	3.4	1
93	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188595	11.2	0
92	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021 , 15, 1178223421995854	2.2	9
91	Bispecific Antibodies. <i>Learning Materials in Biosciences</i> , 2021 , 161-187	0.3	1
90	A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels.		1
89	Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2. <i>Breast Care</i> , 2020 , 15, 579-585	2.4	2
88	Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.. 2020 , 3, 179-198		3

87	Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5365-5379	3.3	7
86	Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019 , 163, 285-292	1.7	3
85	In Silico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment. <i>International Journal of Cancer Management</i> , 2020 , 13,	0.9	6
84	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 313	12.8	2
83	Investigation of The Synergistic Effects of Trastuzumab And Gambogic Acid in Her-2 Positive Breast Cancer Cell Line. <i>Hacettepe Journal of Biology and Chemistry</i> ,	0	
82	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.		1
81	Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. <i>Carbohydrate Polymers</i> , 2022 , 277, 118822	10.3	9
80	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 731148	5.3	1
79	A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation. <i>Life</i> , 2021 , 11,	3	
78	Key genes and drug delivery systems to improve the efficiency of chemotherapy. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2021 , 4, 163-191	4.5	1
77	Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers. <i>Molecular Biology Reports</i> , 2021 ,	2.8	1
76	Accurate Prediction of Breast Cancer Survival through Coherent Voting Networks with Gene Expression Profiling.		
75	The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. <i>Journal of Chemotherapy</i> , 2021 , 1-8	2.3	
74	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. <i>MedComm</i> , 2021 , 2, 514-530	2.2	3
73	Immunotherapy in Breast Cancer: When, How, and What Challenges?. <i>Biomedicines</i> , 2021 , 9,	4.8	7
72	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021 , 10, 77	6.6	0
71	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002). <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
70	Improvement of cytotoxicity and necrosis activity of ganoderic acid a through the development of PMBN-A.Her2-GA as a targeted nano system.. <i>RSC Advances</i> , 2021 , 12, 1228-1237	3.7	0

69	Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.. <i>Cancer Letters</i> , 2022 , 529, 153-167	9.9	1
68	Few, but efficient: the role of mast cells in breast cancer and other solid tumors.. <i>Cancer Research</i> , 2022 ,	10.1	2
67	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211066677	5.4	5
66	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.. <i>Pharmacology & Therapeutics</i> , 2022 , 236, 108108	13.9	4
65	Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.. <i>Cancer and Metastasis Reviews</i> , 2022 , 41, 193	9.6	1
64	Optimizing the future: how mathematical models inform treatment schedules for cancer.. <i>Trends in Cancer</i> , 2022 ,	12.5	1
63	Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1S Cell-Cycle Transition. <i>Cancer Research Communications</i> , 2022 , 2, 131-145		1
62	Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	
61	Mechanosynthesis of phosphonocinnamic esters through solvent-free Horner-Wadsworth-Emmons reaction. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 1-10	1	
60	Boesenbergia pandurata as Anti-breast Cancer: Molecular Docking and ADMET Study. <i>Letters in Drug Design and Discovery</i> , 2021 , 19,	0.8	1
59	. <i>Bulletin Du Cancer</i> , 2021 , 108, 11S8-11S18	2.4	0
58	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.. <i>Cancer Discovery</i> , 2021 ,	24.4	4
57	Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.. <i>Gland Surgery</i> , 2021 , 10, 3389-3402	2.2	0
56	Optimal strategy and benefit of pulsed therapy depend on tumor heterogeneity and aggressiveness at time of treatment initiation.. <i>Molecular Cancer Therapeutics</i> , 2022 ,	6.1	0
55	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.. <i>Breast Cancer: Targets and Therapy</i> , 2022 , 14, 25-39	3.9	1
54	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives.. <i>Cancers</i> , 2022 , 14,	6.6	1
53	Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.. <i>Laryngoscope</i> , 2022 ,	3.6	
52	Receptor tyrosine kinase-like orphan receptors ROR1/2: Insights into the mechanism of action, inhibition, and therapeutic potential. 2022 , 597-621		

51	Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. <i>Thoracic Cancer</i> ,	3.2	0
50	ORLNC1 suppresses cell growth in HER2 positive breast cancer via miRNA-296 sponging. <i>Current Molecular Medicine</i> , 2022 , 22,	2.5	
49	Detection of cell membrane proteins using ion-sensitive field effect transistors combined with chemical signal amplification. <i>Chemical Communications</i> ,	5.8	1
48	Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 12,	5.3	0
47	Glycolipid-peptide conjugate vaccines elicit CD8 + T-cell responses and prevent breast cancer metastasis. <i>Clinical and Translational Immunology</i> , 2022 , 11,	6.8	1
46	Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor. <i>Cancers</i> , 2022 , 14, 3178	6.6	0
45	Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. <i>Cancers</i> , 2022 , 14, 3374	6.6	
44	The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. 2022 , 14, 4-15		2
43	The Epigenetic Regulatory Protein CBX2 Promotes mTORC1 Signalling and Inhibits DREAM Complex Activity to Drive Breast Cancer Cell Growth. <i>Cancers</i> , 2022 , 14, 3491	6.6	1
42	Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study. <i>Cancer Medicine</i> ,	4.8	0
41	TRKB acts as a prognostic predictive marker in Her-2 positive breast cancer. <i>Annals of Diagnostic Pathology</i> , 2022 , 60, 152017	2.2	
40	Pozotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. 2022 , 82, 2928-2939		0
39	CYP2S1 and CYP2W1 expression is associated with patient survival in breast cancer.		
38	Designing a Humanized Immunotoxin Based on HER2 Specific scFv and DFF40 Toxin Against Breast Cancer: An In-Silico Study. 2022 , 28,		
37	Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.		
36	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. 2022 , 13, 1555		1
35	The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. 2022 , 39,		0
34	Refining the definition of HER2 -low class in invasive breast cancer.		1

33	Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.	0
32	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. 2022 , 14, 4543	2
31	Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.	0
30	Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. 2022 ,	0
29	Clinical Efficacy of Pyrotinib Combined with Capecitabine in the Second-Line or Above Treatment for HER-2 Positive Advanced Breast Cancer and Its Association with Cell-Free DNA. 2022 , 2022, 1-10	0
28	Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins. 2022 , 21, 132-139	0
27	Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.	0
26	Design, Synthesis, and In Vitro Mitotic Evaluation of 3-Amino-Isoquinolinones as Anticancer Agents. 2022 , 7,	0
25	Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.	0
24	Liposomes as Targeted Drug-Delivery Systems. 2022 , 69-125	0
23	Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹ At-Labeled Anti-HER2 Single-Domain Antibody Fragment. 2023 , 64, 124-130	0
22	Evaluation of Quantification and Normalization Strategies for Phosphoprotein Phosphatase Affinity Proteomics: Application to Breast Cancer Signaling.	0
21	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. 13,	1
20	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. 2022 , 31, 1203-1226	0
19	The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions. 2022 , 14, 6173	1
18	Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer. Volume 14, 417-432	0
17	ASCO 2022 Breast Cancer Updates. 2022 , 2, 1-10	0
16	Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. 2022 , 11,	1

- 15 Comparative Activity of Chlonisol and Temozolomide in Mice After Intracranial Transplantation of Ehrlich Carcinoma and HER2-Positive Breast Cancer. **2022**, 56, 1179-1182 ○
- 14 Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. 13, 1 ○
- 13 Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies. **2023**, 11, 85 ○
- 12 SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. **2022**, 24, ○
- 11 MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. ○
- 10 Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. **2023**, ○
- 9 131I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer. Volume 18, 1915-1925 ○
- 8 Monoclonal antibodies in breast cancer: A critical appraisal. **2023**, 183, 103915 ○
- 7 The oncogenic roles and clinical implications of YAP/TAZ in breast cancer. ○
- 6 Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. **2023**, 15, 1320 ○
- 5 CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2 / CD98 antibody inhibits the growth signal of human breast cancer cells. ○
- 4 Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer. **2023**, 12, 720 ○
- 3 Baicalein suppresses HER2 -mediated malignant transformation of HER2 -overexpressing ovarian cancer cells by downregulating HER2 gene expression. ○
- 2 Detailed curriculum vitae of HER2-targeted therapy. **2023**, 245, 108417 ○
- 1 High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. 13, ○